Details

Autor(en) / Beteiligte

• Romero, Haylie K.
• Christensen, Sean B.
• Di Cesare Mannelli, Lorenzo
• Gajewiak, Joanna
• Ramachandra, Renuka
• Elmslie, Keith S.
• Vetter, Douglas E.
• Ghelardini, Carla
• Iadonato, Shawn P.
• Mercado, Jose L.
• Olivera, Baldomera M.
• McIntosh, J. Michael

Titel

Inhibition of α9α10 nicotinic acetylcholine receptors prevents chemotherapy-induced neuropathic pain

Ist Teil von

• Proceedings of the National Academy of Sciences - PNAS, 2017-03, Vol.114 (10), p.E1825-E1832

Ort / Verlag

United States: National Academy of Sciences

Erscheinungsjahr

2017

Quelle

MEDLINE

Beschreibungen/Notizen

• Opioids are first-line drugs for moderate to severe acute pain and cancer pain. However, these medications are associated with severe side effects, and whether they are efficacious in treatment of chronic nonmalignant pain remains controversial.Medications that act through alternative molecular mechanisms are critically needed. Antagonists of α9α10 nicotinic acetylcholine receptors (nAChRs) have been proposed as an important nonopioidmechanism based on studies demonstrating prevention of neuropathology after trauma-induced nerve injury. However, the key α9α10 ligands characterized to date are at least two orders of magnitude less potent on human vs. rodent nAChRs, limiting their translational application. Furthermore, an alternative proposal that these ligands achieve their beneficial effects by acting as agonists of GABAB receptors has caused confusion over whether blockade of α9α10 nAChRs is the fundamental underlying mechanism. To address these issues definitively, we developed RgIA4, a peptide that exhibits high potency for both human and rodent α9α10 nAChRs, and was at least 1,000-fold more selective for α9α10 nAChRs vs. all other molecular targets tested, including opioid and GABAB receptors. A daily s.c. dose of RgIA4 prevented chemotherapy-induced neuropathic pain in rats. In wild-type mice, oxaliplatin treatment produced cold allodynia that could be prevented by RgIA4. Additionally, in α9 KO mice, chemotherapy-induced development of cold allodynia was attenuated and the milder, temporary cold allodynia was not relieved by RgIA4. These findings establish blockade of α9-containing nAChRs as the basis for the efficacy of RgIA4, and that α9-containing nAChRs are a critical target for prevention of chronic cancer chemotherapy-induced neuropathic pain.